المؤلفون: Ferreira, João Pedro, Packer, Milton, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart, J., Januzzi, James, L., Sattar, Naveed, Maldonado, Sandra González, Panova-Noeva, Marina, Sumin, Mikhail, Masson, Serge, Anker, Stefan, D., Zannad, Faiez

المساهمون: Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), Cardiovascular R&D Centre-UnIC@RISE, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, Internal Medicine Department, Heart Failure Clinic, Centro Hospitalar de Vila Nova de Gaia/Espinho, Baylor University Medical Center, Baylor College of Medecine, Imperial College London, Baylor Scott & White Research Institute (BSWRI), University of Mississippi Medical Center (UMMC), “Attikon” University Hospital, National and Kapodistrian University of Athens (NKUA), London School of Hygiene and Tropical Medicine (LSHTM), Massachusetts General Hospital Boston, Baim Institute for Clinical Research Boston MA, University of Glasgow, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim International GmbH, Roche Diagnostics International Ltd, Berlin-Brandenburg Center for Regenerative Medicine Berlin, Germany (BCRT), Charité - UniversitätsMedizin = Charité - University Hospital Berlin, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), The EMPEROR-Reduced and Preserved trials were funded by Boehringer Ingelheim and Eli Lilly (EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977 and EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951)

المصدر: ISSN: 1388-9842 ; European Journal of Heart Failure ; https://hal.univ-lorraine.fr/hal-04317427Test ; European Journal of Heart Failure, 2023, ⟨10.1002/ejhf.3078⟩.

مصطلحات موضوعية: Growth differentiation factor-15 Heart failure Empagliflozin Metformin, Growth differentiation factor-15, Heart failure, Empagliflozin, Metformin, [SDV]Life Sciences [q-bio]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37964408; hal-04317427; https://hal.univ-lorraine.fr/hal-04317427Test; https://hal.univ-lorraine.fr/hal-04317427/documentTest; https://hal.univ-lorraine.fr/hal-04317427/file/European%20J%20of%20Heart%20Fail%20-%202023%20-%20Ferreira%20-%20Growth%20differentiation%20factor%E2%80%9015%20and%20the%20effect%20of%20empagliflozin%20in%20heart.pdfTest; PUBMED: 37964408

الإتاحة: https://doi.org/10.1002/ejhf.3078Test
https://hal.univ-lorraine.fr/hal-04317427Test
https://hal.univ-lorraine.fr/hal-04317427/documentTest
https://hal.univ-lorraine.fr/hal-04317427/file/European%20J%20of%20Heart%20Fail%20-%202023%20-%20Ferreira%20-%20Growth%20differentiation%20factor%E2%80%9015%20and%20the%20effect%20of%20empagliflozin%20in%20heart.pdfTest

المؤلفون: Ferreira, João Pedro, Packer, Milton, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart, J., Januzzi, James, L., Sattar, Naveed, Maldonado, Sandra González, Panova-Noeva, Marina, Sumin, Mikhail, Masson, Serge, Anker, Stefan, D., Zannad, Faiez

المساهمون: Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ), Cardiovascular R&D Centre-UnIC@RISE, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, Internal Medicine Department, Heart Failure Clinic, Centro Hospitalar de Vila Nova de Gaia/Espinho, Baylor University Medical Center, Baylor College of Medecine, Imperial College London, Baylor Scott & White Research Institute (BSWRI), University of Mississippi Medical Center (UMMC), “Attikon” University Hospital, National and Kapodistrian University of Athens (NKUA), London School of Hygiene and Tropical Medicine (LSHTM), Massachusetts General Hospital Boston, Baim Institute for Clinical Research Boston MA, University of Glasgow, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim International GmbH, Roche Diagnostics International Ltd, Berlin-Brandenburg Center for Regenerative Medicine Berlin, Germany (BCRT), Charité - UniversitätsMedizin = Charité - University Hospital Berlin, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), The EMPEROR-Reduced and Preserved trials were funded by Boehringer Ingelheim and Eli Lilly (EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977 and EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951)

المصدر: ISSN: 1388-9842 ; European Journal of Heart Failure ; https://hal.univ-lorraine.fr/hal-04317427Test ; European Journal of Heart Failure, 2023, ⟨10.1002/ejhf.3078⟩.

مصطلحات موضوعية: Growth differentiation factor-15 Heart failure Empagliflozin Metformin, Growth differentiation factor-15, Heart failure, Empagliflozin, Metformin, [SDV]Life Sciences [q-bio]

العلاقة: hal-04317427; https://hal.univ-lorraine.fr/hal-04317427Test; https://hal.univ-lorraine.fr/hal-04317427/documentTest; https://hal.univ-lorraine.fr/hal-04317427/file/European%20J%20of%20Heart%20Fail%20-%202023%20-%20Ferreira%20-%20Growth%20differentiation%20factor%E2%80%9015%20and%20the%20effect%20of%20empagliflozin%20in%20heart.pdfTest

الإتاحة: https://doi.org/10.1002/ejhf.3078Test
https://hal.univ-lorraine.fr/hal-04317427Test
https://hal.univ-lorraine.fr/hal-04317427/documentTest
https://hal.univ-lorraine.fr/hal-04317427/file/European%20J%20of%20Heart%20Fail%20-%202023%20-%20Ferreira%20-%20Growth%20differentiation%20factor%E2%80%9015%20and%20the%20effect%20of%20empagliflozin%20in%20heart.pdfTest